Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma
To evaluate the efficacy and safety of TACE combined with adebrelimab and bevacizumab transformation in unresectable hepatocellular carcinoma
Trial Details
- NCT ID
- NCT05970666
- Phase
- PHASE2
- Sponsor
- The First Affiliated Hospital of Xiamen University
- Status
- RECRUITING
- Cancer Type
- Hepatocellular Carcinoma (HCC) Liver Cancer
- Interventions
- TACE with adebrelimab and bevacizumab
- Locations (sample)
- Xiamen, Fujian, China|24.47979,118.08187
Key Eligibility Criteria
- Age: 18 \~ 75, both male and female;
- Strictly comply with the primary liver cancer diagnosis and treatment standard (2022 edition) clinical diagnosis criteria or primary hepatocellular…
- Patients without previous systematic treatment and inoperable resection / radical ablation surgery, but who can tolerate TACE;
- The CNLC stage is Ⅱa-Ⅲb stage;
For full eligibility, visit ClinicalTrials.gov.